Jelena Jordovic1, Jasmina Simonovic-Babic2, Vladimir Gasic3, Nikola Kotur4, Branka Zukic5, Sonja Pavlovic6, Ivana Lazarevic7, Danijela Karalic8, Natasa Katanic9, Natasa Nikolic10, Aleksandar Urosevic11, Jelena Nestorov12, Dragan Delic13, Ksenija Bojovic14. 1. Clinic for Infectious and Tropical Diseases, Clinical Centre of Serbia, Belgrade, Serbia. jelenajejelena@yahoo.com. 2. Clinic for Infectious and Tropical Diseases, Clinical Centre of Serbia, Belgrade, Serbia. jasimba@gmail.com. 3. Laboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia. vladimir.gasic@imgge.bg.ac.rs. 4. Laboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade. nikola.kotur@imgge.bg.ac.rs. 5. Laboratory for Molecular Biomedicine, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade. branka.zukic@imgge.bg.ac.rs. 6. Medical Faculty, University of Belgrade, Belgrade, Serbia. sonya@sezampro.rs. 7. Institute of Microbiology and Immunology, Belgrade, Serbia. ivana.lazarevic@med.bg.ac.rs. 8. Institute of Microbiology and Immunology, Belgrade, Serbia. danijela.karalic@med.bg.ac.rs. 9. Clinic for Infectious and Tropical Diseases, Clinical Centre of Serbia, Belgrade, Serbia. katanicn@gmail.com. 10. Clinic for Infectious and Tropical Diseases, Clinical Centre of Serbia, Belgrade, Serbia. nanika1984@yahoo.com. 11. Clinic for Infectious and Tropical Diseases, Clinical Centre of Serbia, Belgrade, Serbia. uroske@gmail.com. 12. Medical Faculty, University of Belgrade, Belgrade, Serbia. jelenamartinov@yahoo.com. 13. Clinic for Infectious and Tropical Diseases, Clinical Centre of Serbia, Belgrade, Serbia. delic_co@neobee.net. 14. Clinic for Infectious and Tropical Diseases, Clinical Centre of Serbia, Belgrade, Serbia. ksenijabojovi@gmail.com.
Abstract
INTRODUCTION: Patients with severe fibrosis or cirrhosis are at high risk for liver-related complications, even after successful antiviral treatment and/or regression of fibrosis. These are the first published results concerning the role of IL-28B genotypes as predictors of the durability of sustained virological response (SVR) and long-term outcome, in patients with baseline severe fibrosis and cirrhosis caused by hepatitis C (HCV) infection. METHODOLOGY: Genetic testing for three different single nucleotide polymorphisms (SNP) near the IL28B gene, rs12979860, rs12980275 and rs8099917, was performed in 42 patients with HCV-related advanced fibrosis and cirrhosis, who achieved SVR after successful interferon-based treatment. Baseline clinical and laboratory parameters were analysed, as well as IL28B genotype association with late virological relapse, fibrosis progression and clinical outcomes. RESULTS: The most prevalent genotypes in all three tested SNP positions were: CCrs12979860 genotype in 69% of patients, GTrs8099917 in 78.6% and GGrs12980275 in 47.6% of patients. The presence of IL28B CCrs12979860 genotype was identified as a negative predictor of late virological relapse. Further analysis did not confirm the association of other IL28B genotypes with the progression of fibrosis and clinical outcomes. CONCLUSIONS: Varying long-term prognosis in patients with HCV-related severe fibrosis and cirrhosis is due to multiple interactions between host genetic factors, virus and environment. These are first published results demonstrating the significance of IL28B CCrs12979860 genotype as a negative predictor of late virological relapse. A further investigation concerning genetic factors is necessary to identify patients under risk for late relapse, complications and unfavorable outcomes, so that they can be reevaluated and offered new treatment options. Copyright (c) 2019 Jelena Jordovic, Jasmina Simonovic-Babic, Vladimir Gasic, Nikola Kotur, Branka Zukic, Sonja Pavlovic, Ivana Lazarevic, Danijela Karalic, Natasa Katanic, Natasa Nikolic, Aleksandar Urosevic, Jelena Nestorov, Dragan Delic, Ksenija Bojovic.
INTRODUCTION:Patients with severe fibrosis or cirrhosis are at high risk for liver-related complications, even after successful antiviral treatment and/or regression of fibrosis. These are the first published results concerning the role of IL-28B genotypes as predictors of the durability of sustained virological response (SVR) and long-term outcome, in patients with baseline severe fibrosis and cirrhosis caused by hepatitis C (HCV) infection. METHODOLOGY: Genetic testing for three different single nucleotide polymorphisms (SNP) near the IL28B gene, rs12979860, rs12980275 and rs8099917, was performed in 42 patients with HCV-related advanced fibrosis and cirrhosis, who achieved SVR after successful interferon-based treatment. Baseline clinical and laboratory parameters were analysed, as well as IL28B genotype association with late virological relapse, fibrosis progression and clinical outcomes. RESULTS: The most prevalent genotypes in all three tested SNP positions were: CCrs12979860 genotype in 69% of patients, GTrs8099917 in 78.6% and GGrs12980275 in 47.6% of patients. The presence of IL28B CCrs12979860 genotype was identified as a negative predictor of late virological relapse. Further analysis did not confirm the association of other IL28B genotypes with the progression of fibrosis and clinical outcomes. CONCLUSIONS: Varying long-term prognosis in patients with HCV-related severe fibrosis and cirrhosis is due to multiple interactions between host genetic factors, virus and environment. These are first published results demonstrating the significance of IL28B CCrs12979860 genotype as a negative predictor of late virological relapse. A further investigation concerning genetic factors is necessary to identify patients under risk for late relapse, complications and unfavorable outcomes, so that they can be reevaluated and offered new treatment options. Copyright (c) 2019 Jelena Jordovic, Jasmina Simonovic-Babic, Vladimir Gasic, Nikola Kotur, Branka Zukic, Sonja Pavlovic, Ivana Lazarevic, Danijela Karalic, Natasa Katanic, Natasa Nikolic, Aleksandar Urosevic, Jelena Nestorov, Dragan Delic, Ksenija Bojovic.